Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...
Takeaways: The decision should expand use of Keytruda plus enfortumab vedotin in the perioperative setting by giving oncologists a data-backed option that improves event-free...